ProQR triumphs in Japan patent fight with RNA editing breakthrough.

ProQR wins patent dispute in Japan for RNA editing technology

ProQR Therapeutics N.V., a biopharmaceutical company specializing in RNA therapies, has won a patent dispute in Japan for its proprietary Axiomer RNA editing platform. The patent involves the use of modified oligonucleotides for targeted RNA editing and was upheld against an opposition filed in September 2023. The Japanese Patent Office confirmed the novelty and inventiveness of the claims, maintaining the patent’s validity and reinforcing ProQR’s intellectual property (IP) position in the RNA editing field.

The company’s Axiomer platform, patented in 2014, enables precise RNA editing using the body’s